The Evolution of Antibody-Drug Conjugates (ADCs): Opportunities and Challenges
At this year’s AACR annual meeting, there were hundreds of details related to ADC drugs. Leading ADC company Daiichi Sankyo announced the latest research progress of its HER3-targeted ADC product Patritumab deruxtecan (HER3-DXd); AstraZeneca also disclosed research updates on several drugs including AZD9592 (bispecific ADC) and AZD5335 (FRα ADC). Many Chinese pharmaceutical companies also showcased … Read more